Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2062948 | 1.00 | PTGDR2 (0.45) | PTGDR2LMNAMAPK1PTGDRKMO | |
| SCHEMBL415803 | 1.00 | PTGDR2 (0.45) | PTGDR2LMNAMAPK1PTGDRKMO | |
| SCHEMBL198311 | 0.98 | PTGDR2 (0.48) | PTGDR2LMNAMAPK1PTGDRKMO | |
| SCHEMBL198081 | 0.98 | PTGDR2 (0.48) | PTGDR2LMNAMAPK1PTGDRKMO | |
| SCHEMBL1825802 | 0.98 | PTGDR2 (0.48) | PTGDR2LMNAMAPK1PTGDRKMO | |
| SCHEMBL30913266 | 0.98 | PTGDR2 (0.48) | PTGDR2LMNAMAPK1PTGDRKMO | |
| Hydrochloric Acid SCHEMBL8869405 | 0.97 | PTGDR2 (0.47) | PTGDR2LMNAMAPK1PTGDRKMO | |
| SCHEMBL2062720 | 0.86 | PTGDR2 (0.42) | PTGDR2USP2CYP1A2HTR1AADRA2A | |
| SCHEMBL28336946 | 0.83 | PTGDR2 (0.43) | PTGDR2LMNAPTGDRKMOUSP2 | |
| SCHEMBL7919662 | 0.83 | PTGDR2 (0.43) | PTGDR2KMOKDM4EPTGS2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114008023-B | Crystal form of Sofos-piramide and preparation method thereof | 科研制药株式会社 | 2024-02-09 | — | — | CN | disclosed |
| US-11584715-B2 | Crystalline form of sofpironium bromide and preparation method thereof | BOTANIX SB, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11566000-B2 | Crystalline form of sofpironium bromide and preparation method thereof | BOTANIX SB, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220298108-A1 | CRYSTALLINE FORM OF SOFPIRONIUM BROMIDE AND PREPARATION METHOD THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2022-09-22 | — | — | US | disclosed |
| US-11447485-B2 | Class of bifunctional compounds with quanternary ammonium salt structure | BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) | 2022-09-20 | — | — | US | disclosed |
| EP-3494106-B1 | PROCESSES FOR MAKING, AND METHODS OF USING, GLYCOPYRRONIUM COMPOUNDS | JOURNEY MEDICAL CORP (US) | 2022-07-20 | — | — | EP | disclosed |
| US-11352323-B2 | Processes for making, and methods of using, glycopyrronium compounds | JOURNEY MEDICAL CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352323-B2 | Processes for making, and methods of using, glycopyrronium compounds | JOURNEY MEDICAL CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| CN-110087729-B | Bifunctional compound with quaternary ammonium salt structure | 北京硕佰医药科技有限责任公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-3972955-A1 | CRYSTALLINE FORM OF SOFPIRONIUM BROMIDE AND PREPARATION METHOD THEREOF | Kaken Pharmaceutical Co., Ltd. (JP) | 2022-03-30 | — | — | EP | disclosed |
| US-20090263341-A1 | SOFT ANTICHOLINERGIC ESTERS | BODOR LABORATORIES, INC. | 2009-10-22 | — | — | US | disclosed |
| US-7576210-B2 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives; 6 beta ,7 beta -epoxy-3 beta -hydroxy-8-ethoxycarbonylmethyl-8-methyl-1 alpha H,5 alpha H-tropanium bromide, di-2-thienylglycolate | BODOR LABORATORIES, INC. | 2009-08-18 | — | — | US | disclosed |
| US-20090075954-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives; 6 beta ,7 beta -epoxy-3 beta -hydroxy-8-ethoxycarbonylmethyl-8-methyl-1 alpha H,5 alpha H-tropanium bromide, di-2-thienylglycolate | BODOR LABORATORIES, INC. | 2009-03-19 | — | — | US | disclosed |
| EP-2032118-A1 | PIPERIDINIUM COMPOUNDS AND COSMETIC COMPOSITIONS CONTAINING THEM | Beiersdorf AG (DE) | 2009-03-11 | — | — | EP | disclosed |
| EP-1948596-A2 | SOFT ANTICHOLINERGIC ESTERS | Bodor, Nicholas S. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-7399861-B2 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | BODOR LABORATORIES, INC. | 2008-07-15 | — | — | US | disclosed |
| US-20070292375-A1 | Piperidinium compounds and cosmetic compositions containing them | BEIERSDORF AG (DE) | 2007-12-20 | — | — | US | disclosed |
| WO-2007141289-A1 | PIPERIDINIUM COMPOUNDS AND COSMETIC COMPOSITIONS CONTAINING THEM | BEIERSDORF AG (DE) | 2007-12-13 | — | — | WO | disclosed |
| US-20070123557-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | BODOR LABORATORIES, INC. | 2007-05-31 | — | — | US | disclosed |
| WO-2007058971-A2 | SOFT ANTICHOLINERGIC ESTERS | BODOR NICHOLAS S (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070292375-A1 | Piperidinium compounds and cosmetic compositions containing them | CUTA, DPM1, TRPA1 | PTGDR2 2610/4885LMNA 4213/4885MAPK1 2528/4885 |
| US-20090263341-A1 | SOFT ANTICHOLINERGIC ESTERS | CHRM2, CHRM1, CHRM3 | PTGDR2 553/4885LMNA 1719/4885MAPK1 3903/4885 |
| US-11584715-B2 | Crystalline form of sofpironium bromide and preparation method thereof | POLR2B, COPB2, FXR1 | PTGDR2 4330/4885LMNA 3629/4885MAPK1 3342/4885 |
| US-11447485-B2 | Class of bifunctional compounds with quanternary ammonium salt structure | AGTR2, AGTR1, ADRB2 | PTGDR2 603/4885LMNA 2541/4885MAPK1 1617/4885 |
| US-11566000-B2 | Crystalline form of sofpironium bromide and preparation method thereof | POLR2B, COPB2, FXR1 | PTGDR2 4338/4885LMNA 3660/4885MAPK1 3267/4885 |
| US-11352323-B2 | Processes for making, and methods of using, glycopyrronium compounds | GYPA, TPO, CYP21A2 | PTGDR2 1038/4885LMNA 4304/4885MAPK1 4233/4885 |
| US-20090075954-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives; 6 beta ,7 beta -epoxy-3 beta -hydroxy-8-ethoxycarbonylmethyl-8-methyl-1 alpha H,5 alpha H-tropanium bromide, di-2-thienylglycolate | CHRNE, CHRM1, ADRB1 | PTGDR2 294/4885LMNA 3526/4885MAPK1 2380/4885 |
| US-20070123557-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | CHRM2, ADRB1, ADRB2 | PTGDR2 256/4885LMNA 3178/4885MAPK1 3385/4885 |
| US-20220298108-A1 | CRYSTALLINE FORM OF SOFPIRONIUM BROMIDE AND PREPARATION METHOD THEREOF | POLR2B, COPB2, FXR1 | PTGDR2 4330/4885LMNA 3629/4885MAPK1 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.